Systems-biology dissection of mechanisms and chemical basis of herbal formula in treating chronic myocardial ischemia.

[1]  Jianxin Chen,et al.  Chinese Herbal Medicine in the Treatment of Chronic Heart Failure: Three-Stage Study Protocol for a Randomized Controlled Trial , 2015, Evidence-based complementary and alternative medicine : eCAM.

[2]  Peng Li,et al.  Insights from systems pharmacology into cardiovascular drug discovery and therapy , 2014, BMC Systems Biology.

[3]  Peng Yang,et al.  Microbial community pattern detection in human body habitats via ensemble clustering framework , 2014, BMC Systems Biology.

[4]  Huajun Chen,et al.  Modern bioinformatics meets traditional Chinese medicine , 2014, Briefings Bioinform..

[5]  Johannes M. I. H. Gho,et al.  Myocardial Infarction and Functional Outcome Assessment in Pigs , 2014, Journal of visualized experiments : JoVE.

[6]  Wei Wang,et al.  Time-Course of the Effects of QSYQ in Promoting Heart Function in Ameroid Constrictor-Induced Myocardial Ischemia Pigs , 2014, Evidence-based complementary and alternative medicine : eCAM.

[7]  Mark A Sussman,et al.  Fibronectin contributes to pathological cardiac hypertrophy but not physiological growth , 2013, Basic Research in Cardiology.

[8]  P. Clemons,et al.  Target identification and mechanism of action in chemical biology and drug discovery. , 2013, Nature chemical biology.

[9]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[10]  J. Molkentin,et al.  Signaling effectors underlying pathologic growth and remodeling of the heart. , 2013, The Journal of clinical investigation.

[11]  R. Hajjar,et al.  Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy , 2012, Nature Reviews Cardiology.

[12]  Wei Wang,et al.  Cardioprotective Effects of Qishenyiqi Mediated by Angiotensin II Type 1 Receptor Blockade and Enhancing Angiotensin-Converting Enzyme 2 , 2012, Evidence-based complementary and alternative medicine : eCAM.

[13]  J. Loscalzo,et al.  The Emerging Paradigm of Network Medicine in the Study of Human Disease , 2012, Circulation research.

[14]  Arthur N Westover,et al.  Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review , 2012, BMC Cardiovascular Disorders.

[15]  Wei Wang,et al.  Drug Target Prediction Based on the Herbs Components: The Study on the Multitargets Pharmacological Mechanism of Qishenkeli Acting on the Coronary Heart Disease , 2012, Evidence-based complementary and alternative medicine : eCAM.

[16]  W. Chan,et al.  New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients--a matter of time for contractility. , 2012, Journal of cardiac failure.

[17]  E. Rodríguez-Sánchez,et al.  Ambulatory arterial stiffness indices and target organ damage in hypertension , 2012, BMC Cardiovascular Disorders.

[18]  F. Cheung.  TCM: Made in China , 2011, Nature.

[19]  V. Gewin.  Turning point: Jonathan Cirtain , 2011, Nature.

[20]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[21]  Patrick M. McLendon,et al.  Desmin-related cardiomyopathy: an unfolding story. , 2011, American journal of physiology. Heart and circulatory physiology.

[22]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[23]  M. Galsky,et al.  Docetaxel-based combination therapy for castration-resistant prostate cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  J. Tamargo,et al.  New investigational drugs for the management of acute heart failure syndromes. , 2010, Current medicinal chemistry.

[25]  Adriano Lazzarin,et al.  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial , 2009, The Lancet.

[26]  N. Turner,et al.  Cardiac fibroblasts: at the heart of myocardial remodeling. , 2009, Pharmacology & therapeutics.

[27]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial , 2009, The Lancet.

[28]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[29]  De-Xin Kong,et al.  Where is the hope for drug discovery? Let history tell the future. , 2009, Drug discovery today.

[30]  A. Hoes,et al.  Clinical epidemiology of heart failure , 2007, Heart.

[31]  L. Opie,et al.  Metabolic mechanisms in heart failure. , 2007, Circulation.

[32]  J. Qiu.  News feature: 'Back to the future' for Chinese herbal medicines , 2007, Nature Reviews Drug Discovery.

[33]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[34]  H. Krum,et al.  Drug discovery for heart failure: a new era or the end of the pipeline? , 2007, Nature Reviews Drug Discovery.

[35]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[36]  J. Molkentin,et al.  Regulation of cardiac hypertrophy by intracellular signalling pathways , 2006, Nature Reviews Molecular Cell Biology.

[37]  H. Kitano.  Cancer as a robust system: implications for anticancer therapy , 2004, Nature Reviews Cancer.

[38]  D. Coates.  The angiotensin converting enzyme (ACE). , 2003, The international journal of biochemistry & cell biology.

[39]  AlanMaisel.  B-Type Natriuretic Peptide Levels: Diagnostic and Prognostic in Congestive Heart Failure , 2002 .

[40]  A. Maisel,et al.  B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? , 2002, Circulation.

[41]  J. Huss,et al.  PPAR signaling in the control of cardiac energy metabolism. , 2000, Trends in cardiovascular medicine.

[42]  J. Schaper,et al.  The role of the cytoskeleton in heart failure. , 2000, Cardiovascular research.

[43]  M. K. Magnússon,et al.  Fibronectin: structure, assembly, and cardiovascular implications. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[44]  C. Wayman,et al.  Capacitative Ca2+ entry and the regulation of smooth muscle tone. , 1998, Trends in pharmacological sciences.

[45]  Robert H. Anderson,et al.  Anatomy of the pig heart: comparisons with normal human cardiac structure , 1998, Journal of anatomy.

[46]  D Hare,et al.  The Orange Book: the Food and Drug Administration's advice on therapeutic equivalence. , 1990, American pharmacy.

[47]  W. Yao,et al.  A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. , 2013, Journal of the American College of Cardiology.

[48]  Maarten L. Simoons,et al.  The third universal definition of myocardial infarction , 2013 .

[49]  A. Papavassiliou,et al.  The role of inflammation in heart failure: new therapeutic approaches. , 2011, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[50]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[51]  C. Long,et al.  The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. , 2005, Annual review of pharmacology and toxicology.

[52]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.